Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data show epirubicin hydrochloride injection improves survival
December 28th, 2004
Results of a study presented at the 27th Annual San Antonio Breast Cancer Symposium show that an Ellence (epirubicin hydrochloride injection; Pfizer Inc.) based chemotherapy regimen delivers survival benefits when used alone or in combination with docetaxel. The results of the study, which compares a sequential regimen of FEC 100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by docetaxel 100 mg/m2 to FEC 100 alone, builds upon an existing body of survival and safety evidence for Ellence including previously reported 10-year disease-free and overall survival data. In both arms of the study,...
Source: Cancer Weekly (2004-12-28)
|
